PhRMA sees strong FDA centers
Bush Administration FDA commissioner choice will not alter the "strong leadership role" played by the FDA centers, Pharmaceutical Research & Manufacturers of America Senior VP-Scientific & Regulatory Affairs Bert Spilker, MD/PhD, predicts at April 2 DIA meeting in Washington, D.C. "Most FDA commissioners previously have allowed the center directors to maintain their relative degree of independence...While the new FDA commissioner might in his or her view try to influence that, we see that major activities will still remain at the center"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth